Sun Pharma Q4 earnings today: Here are the key things to watch out for
Sun Pharmaceuticals Industries Ltd will release its fourth-quarter earnings on Tuesday. Here are the key things to watch out for
Sun Pharmaceuticals Industries Ltd will release its fourth-quarter earnings on Tuesday. All eyes will be on domestic business restructuring wherein they have shifted the Aditya Medisales operations to a wholly owned subsidiary and there could be a one-time impact on account of that.
However, Sun Pharma's US business may see some rise a quarter-on-quarter basis by around $5-7 million, which will be aided by their speciality portfolio. The management commentary will be important in terms of plans and scale-up of the speciality business.
The Street will also be keen to know about a Sebi probe. A lot of corporate governance overhang for Sun Pharma has been lifted to a large extent because of the kind of proactive steps the company took after the issues cropped up.
Key things to watch out for
-Improved performance in-line with guidance
-The company had said H2 performance will be better than H1
-US pricing more stable
-Expect a subdued quarter
-Rejigs domestic business and ramps up spend for speciality portfolio
Q4FY19 (YoY): CNBC-TV18 Poll
-Revenue seen (GU) 5.7 percent at Rs 7,375 crore vs Rs 6,977 crore
-EBITDA seen (RD) 5.5 percent at Rs 1,591.1 crore vs Rs 1,683.5 crore
-Margins likely at (RD) 21.6 percent vs 24.1 percent
-Profit expected (RD) at Rs 861.62 crore vs Rs 1,309 crore
Q4FY19: Key Expectations
-Street factoring in a one-time reduction in domestic sales of Rs 1,000 crore
-Transition in the distribution of India domestic formulations from Aditya Medisales
-Transition in the distribution of India domestic formulations to a wholly-owned subsidiary
-US sales expected to be flat
-US sales may grow marginally QoQ driven by a ramp-up in speciality drug, Illumya
-Expect around 7-10 percent growth in US biz (YoY)
-Illumya estimated to be around $40 m of sales on an annualised basis
-Last quarter was challenging on account of lack of meaningful launches, pricing pressure
-New approvals in US: Ganirelix Acetate injection, Lialda generic & Retin generic
-Expect margins to be under pressure
First Published: May 28, 2019 8:40 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Lok Sabha Election 2024: Phase 5 voting concludes with over 57% voter turnout, experts weigh in on key battles
May 20, 2024 11:07 PM
BJP holds meeting in Delhi as polling underway for 5th phase
May 20, 2024 4:21 PM
UP Police arrests man after viral videos shows him voting multiple times
May 20, 2024 2:18 PM